IL 17E Human
Description
Biological Functions
2.1 Th2 Immunity Modulation
IL-17E drives type 2 immune responses through:
Inflammatory Roles
| Disease Model | Observed Effects |
|---|---|
| Psoriasis | ↑ Neutrophil infiltration |
| Atopic Dermatitis | ↑ Macrophage activation |
| Asthma | ↑ Airway hyperresponsiveness |
| Helminth Infection | Enhanced parasite clearance |
2.3 Antitumor Activity
Key findings from xenograft studies :
-
57% tumor growth inhibition in melanoma models
-
Synergy with chemotherapy (e.g., 72% reduction with CPT-11 combo in colon cancer)
-
B-cell dependent mechanism (p < 0.01 vs SCID controls)
-
Dose-dependent eosinophil mobilization (r²=0.89 correlation with efficacy)
Signaling Mechanisms
Receptor Complex
| Component | Expression Pattern | Key Interaction |
|---|---|---|
| IL-17RA | Ubiquitous | Co-receptor for signaling |
| IL-17RB | Th2 cells, eosinophils | Primary binding subunit |
Downstream Pathways
Clinical Relevance
4.1 Diagnostic Applications
The Human IL-17E/IL-25 XL Luminex® Assay demonstrates :
| Parameter | Performance Data |
|---|---|
| Sensitivity (MDD) | 1.95 pg/mL (mean) |
| Linear Range | 1.88-4.95 pg/mL |
| Cross-reactivity | <0.1% with IL-17B |
| Sample Types | Serum, plasma, CSF |
Therapeutic Potential
-
Phase I trial data shows IL-17E increases peripheral eosinophils by 3.8-fold (p=0.002)
-
Combination with anti-PD1 improves tumor regression rates from 22% to 41% in murine models
-
Topical anti-IL-17E antibodies reduce psoriatic lesion scores by 58%
Research Tools
Key Reagents
-
AF1258 Antibody: Detects 0.2 ng/mL in ELISA with <0.5% cross-reactivity
-
Recombinant Protein (1258-IL): Bioactivity confirmed by TF-1 cell proliferation assay (ED₅₀=12-25 ng/mL)
Experimental Considerations
Comparative Analysis Within IL-17 Family
| Cytokine | Primary Source | Immune Polarization | Key Functions |
|---|---|---|---|
| IL-17A | Th17 cells | Th1/Th17 | Antimicrobial defense |
| IL-17E | Th2 cells, epithelia | Th2 | Allergy, antitumor immunity |
| IL-17F | Th17 cells | Th1/Th17 | Mucosal protection |
Future Directions
Product Specs
Purity exceeds 95.0%, as determined by SDS-PAGE analysis.
The effective concentration that results in 50% of the maximum response (ED50) is measured by the dose-dependent production of IL-8 by human PBMCs. This value is 26-40 ng/ml, which corresponds to a specific activity of 3.8 x 104 units/mg.
Product Science Overview
IL-17E is a proinflammatory cytokine that is produced by various cell types, including Th17 effector cells. The recombinant form of IL-17E is typically produced in E. coli or HEK293 cells. The recombinant protein is a disulfide-linked homodimer, consisting of two polypeptide chains. The molecular weight of IL-17E is approximately 33.8 kDa .
IL-17E is known for its ability to induce the activation of NF-kappaB and stimulate the production of IL-8, a chemokine involved in the inflammatory response . It also promotes a Th2-biased immune response, which is in contrast to other IL-17 family members that typically promote Th1- and Th17-biased inflammation . This makes IL-17E a key player in the regulation of immune responses, particularly in the context of autoimmune diseases such as rheumatoid arthritis .
IL-17E exerts its effects by binding to the IL-17BR receptor. This interaction triggers a cascade of signaling events that lead to the activation of various transcription factors, including NF-kappaB. The activation of these transcription factors results in the production of proinflammatory cytokines and chemokines, which contribute to the immune response .
Recombinant IL-17E is widely used in research to study its role in immune regulation and its potential therapeutic applications. It is used in various assays, including Western Blot (WB), ELISA, and Functional Assays (FN) . Researchers are particularly interested in IL-17E’s potential to modulate immune responses and its implications in autoimmune diseases and inflammatory conditions.
